Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.17Sunrest Lifescience Ltd demonstrates a mixed financial performance. The company shows strengths in profitability, driven by strong gross, operating, and net profit margins. Its coverage ratios are adequate, particularly regarding interest obligations. However, the company faces challenges in liquidity, growth, and efficiency, indicating potential difficulties in meeting short-term obligations and leveraging assets effectively. Financial ratios are also weak, suggesting limited earnings and book value per share. While the company's profitability and coverage offer some stability, addressing the weaknesses in liquidity, growth, efficiency, and financial metrics is crucial for sustained financial health and future success. The healthcare industry's dynamics, including regulatory changes and competitive pressures, could further impact the company's performance.
Health Score : 4.17Sunrest Lifescience Ltd demonstrates a mixed financial performance. The company shows strengths in profitability, driven by strong gross, operating, and net profit margins. Its coverage ratios are adequate, particularly regarding interest obligations. However, the company faces challenges in liquidity, growth, and efficiency, indicating potential difficulties in meeting short-term obligations and leveraging assets effectively. Financial ratios are also weak, suggesting limited earnings and book value per share. While the company's profitability and coverage offer some stability, addressing the weaknesses in liquidity, growth, efficiency, and financial metrics is crucial for sustained financial health and future success. The healthcare industry's dynamics, including regulatory changes and competitive pressures, could further impact the company's performance.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
10.14
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
7.60
P/B RATIO
1.53
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
0.42
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.03
EV/EBITDA RATIO
3.05
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹36.5 as on Sep 1, 2026.
Growth Score : 2.00The company's growth ratios are weak, indicating limited expansion in revenue, operating profit, earnings per share, assets, and net income. This raises concerns about the company's ability to capitalize on market opportunities and sustain long-term growth. Without significant growth, the company may struggle to attract investors and maintain its competitive position in the market. Strategic initiatives are needed to stimulate growth across various financial metrics.
Revenue Growth RatePoorOperating Profit Growth RatePoorEarnings Per Share (EPS) GrowthPoorAsset Growth RatePoorNet Income Growth RatePoor| Growth Ratios | Mar 2026 |
|---|---|
| Revenue Growth Rate | 112 |
| Operating Profit Growth Rate | 236.96 |
| Earnings Per Share (EPS) Growth | 105.13 |
| Asset Growth Rate | 21.76 |
| Net Income Growth Rate | 296.04 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Sunrest Lifescience Ltd | 4.17 | 7.60 | Highly Undervalued | 10.21 | 3.60 | 8.00 |
| 2 | Ortin Global Ltd | 3.45 | -17.43 | Neutral | -0.72 | -0.91 | -0.74 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Sunrest Lifescience Ltd is an Indian pharmaceutical company engaged in marketing, trading, and distribution of a diverse range of pharma formulations including nutraceuticals, cosmeceuticals, and dermatological products. Operating on a contract manufacturing basis, the company focuses on serving various therapeutic segments across India.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Sunrest Lifescience Ltd's P/E ratio (TTM) is 10.14, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Sunrest Lifescience Ltd's P/B ratio is 1.53, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Sunrest Lifescience Ltd's P/S ratio is 0.42, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Sunrest Lifescience Ltd's PEG ratio is 0.03.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Sunrest Lifescience Ltd's EV/EBITDA ratio is 3.05.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Sunrest Lifescience Ltd's ROE is 39.16%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Sunrest Lifescience Ltd's ROA is 14.30%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Sunrest Lifescience Ltd's ROCE is 28.55%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Sunrest Lifescience Ltd's operating margin is 14.41%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Sunrest Lifescience Ltd's net margin is 11.29%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Sunrest Lifescience Ltd's current ratio is 1.61.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Sunrest Lifescience Ltd's debt-to-equity ratio is 0.59.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Sunrest Lifescience Ltd's interest coverage ratio is 8.12.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Sunrest Lifescience Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Sunrest Lifescience Ltd's EPS is 105.13.
(Source line: "Ratios as of 26 Sept 2026, based on last traded price of ₹36.50. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2017
Headquarters: Ahmedabad, Gujarat
Core Offerings: Pharmaceutical formulations (nutraceuticals, cosmeceuticals, dermatologicals), trading, distribution, marketing
Stock Listing: NSE (SUNREST), BSE ({bse})
Promoter: Dr. Rahul N. Vashi, Mr. Naitik V. Shah, Mr. Yogesh N. Shah
Incorporated in March 2017 in Ahmedabad, Gujarat, Sunrest Lifescience Ltd commenced operations focusing on the marketing and distribution of pharmaceutical products. The company later successfully completed its Initial Public Offering (IPO) and was listed on the NSE SME platform in November 2022, marking a significant milestone in its growth trajectory.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Business (Marketing & Distribution) | 100% | N/A (Segment-wise EBITDA not reported) |
Pharmaceutical Formulations: Engages in marketing and distribution of a wide array of pharmaceutical products, covering therapeutic areas such as nutraceuticals, cosmeceuticals, dermatologicals, cardiac, diabetic, anti-allergic, and anti-infectives.
Contract Manufacturing Model: Operates on a contract manufacturing basis, outsourcing production to third-party manufacturers while focusing on product development, branding, and an extensive distribution network across India.
Dr. Rahul N. Vashi, Chairman & Whole Time Director. He is a qualified doctor and one of the founders, instrumental in establishing the company's product portfolio and market presence.
No major subsidiaries reported.
Initial Public Offering (IPO) on NSE SME in November 2022. No other major recent corporate actions on record.
The Sunrest Lifescience Ltd share price today is ₹36.50 on NSE (SUNREST), as of 26 Sept 2026.
As of 26 Sept 2026, Sunrest Lifescience Ltd share price is ₹36.50, with previous close ₹36.50. Today's range is ₹36.50 to ₹36.50. The 52-week range is ₹N/A to ₹N/A.
As of today, Sunrest Lifescience Ltd's market cap is ₹29.57 crore (Small Cap).
Sunrest Lifescience Ltd's current P/E ratio is 10.14, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 32.50.
Sunrest Lifescience Ltd's current P/B ratio is 1.53.
Sunrest Lifescience Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Sunrest Lifescience Ltd's EPS (TTM) is ₹105.13.
Sunrest Lifescience Ltd is an Indian pharmaceutical company engaged in marketing, trading, and distribution of a diverse range of pharma formulations including nutraceuticals, cosmeceuticals, and dermatological products. Operating on a contract manufacturing basis, the company focuses on serving various therapeutic segments across India.
Sunrest Lifescience Ltd is promoted by Dr. Rahul N. Vashi, Mr. Naitik V. Shah, Mr. Yogesh N. Shah, holding 53.5% as of 26 Sept 2026.
Sunrest Lifescience Ltd is listed on NSE (SUNREST) and BSE ({bse}). Its next quarterly results are expected on Q1 FY25 (Expected July/August 2024).
